This study is looking at how a treatment called Extracorporeal Photopheresis (ECP) works in people with Sezary syndrome, a type of skin lymphoma. ECP involves treating your white blood cells and plasma with a light-sensitizing drug called Methoxsalen outside your body, then returning them. Researchers want to see if ECP can reduce the percentage of tumor cells in your body. They plan to enroll 20 adults, aged 18 to 100, who have Sezary syndrome and can receive ECP. To be eligible, you also need to have recovered from any side effects of previous treatments. Participants will receive ECP weekly for four weeks, then every two weeks for five months. The study will measure changes in your body's immune response against tumor cells over three and six months to see how well the treatment works.

Study design

This is an observational study planning to enroll 20 participants with Sezary syndrome. It is not a randomized study.

What's involved

You would receive ECP weekly for 4 weeks, then twice monthly for 5 months. You would also provide 5 blood samples and have skin assessments and flow cytometry at baseline, 3, and 6 months.

Compensation

Not stated in the trial record.

Follow-up

Your immune responses will be measured up to 6 months after starting ECP treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.